RAPP MEXC RealStocks
Own real RAPP shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:14:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rapport Therapeutics, Inc. (RAPP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.41, with a market capitalization of $1.47B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.06 to $52.93. This page covers its latest market performance, valuation, price trends and company information.
$1.47B | |
$23.70 | |
$24.66 | |
$22.94 | |
$23.76 | |
546.40K | |
787.71K | |
-- | |
$52.93 | |
$22.06 | |
-- | |
2026-09-30 |
Rapport Therapeutics, Inc. (RAPP) last closed at $23.41 as of 2026-11-19 00:56:00, down 1.54% ($0.37) from the previous close of $23.76.
During the latest regular trading session, RAPP traded between $22.94 and $24.66, with a volume of 546.40K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Rapport Therapeutics, Inc. (RAPP) moved from $26.07 to $23.41, representing a decline of 10.19% ($2.66).
The stock traded between $22.94 and $27.10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 565.01 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.4%
RAPP is currently trading at $23.41, placing it 4.4% of the way from its 52-week low of $22.06 to its 52-week high of $52.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 84 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rapport Therapeutics, Inc. (RAPP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RAPP, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RAPP shares and USD.
RAPP Shares to USD
1.00 RAPP shares = 23.414 USD
Calculations are estimates based on the latest available price and are for reference only.